Representatives from UniSA and corporate sponsor Duncan Basheer Hannon and staff and clients of Muscular Dystrophy South Australia were present for the announcement.
Muscular Dystrophy South Australia are thrilled to be entering a partnership with leading South Australia researchers through the University of South Australia.
The research project, which will investigate the genetic causes of neuromuscular conditions, will be led by Professor Leanne Dibbens and was made possible through an investment of $75,000 by Muscular Dystrophy South Australia.
This project clearly aligns to our organisation’s vision of a world without neuromuscular conditions by 2050.
CEO David Duncan says, “Muscular Dystrophy South Australia has actively been looking to invest in a research project that will explore and hopefully uncover new ways to prevent, treat and possibly one day cure neuromuscular conditions.”
To have a nationally and internationally recognised researcher such as Professor Leanne Dibbens and her great team provides Muscular Dystrophy SA with confidence of a long term commitment to this work.
It is also clear that the project aligns with our purpose, “to provide supports and services to people living with a neuromuscular condition and their families and to support research to find a cure and improved clinical practice.”
In essence this provides the fourth “arm” of activity whereby Muscular Dystrophy SA
- supports research to prevent or treat (and possibly cure) neuromuscular conditions
- works with hospitals to advance clinical trials and robust neuromuscular clinics
- supports the development of registries to better inform advocacy and lobbying for future funding and supports form government and private benefactors
- provides practical support and services through our client services team to improve the quality of live for people living with a neuromuscular condition and their families
David Duncan says, “Muscular Dystrophy South Australia is delighted to support the University of South Australia research team and look forward to working with them in the global race to find a cure by 2050.”